Study first to evaluate prevalence, impact of off label chemotherapy in breast cancer

At some point during their care, more than one-third of metastatic breast cancer patients receive chemotherapy off label, the legal use of FDA-approved drugs in a different indication than for which they were approved, according to researchers at The University of Texas M. D. Anderson Cancer Center.

If you want to include this story in your blog, copy and paste this formatted text:

<p><a href="http://www.physorg.com/news161610244.html">Study first to evaluate prevalence, impact of off label chemotherapy in breast cancer</a></p> <p>At some point during their care, more than one-third of metastatic breast cancer patients receive chemotherapy off label, the legal use of FDA-approved drugs in a different indication than for which they were approved, according to researchers at The University of Texas M. D. Anderson Cancer Center.</p>